UBS considers Elior Group's Q1 2023 results to be broadly in line. Following this publication, the research firm confirms its neutral recommendation on the stock, with a target price of E3.2.

Elior reported sales of €2,478 million (vs. €2,444 million expected by UBSe, consensus €2,440 million) in the first half of 2023, with organic growth of 14.1% (UBSe 10.9%, consensus 12.3%), adjusted EBITA of €41 million (UBSe €35 million, consensus €42 million), and a margin of 1.7%', says UBS.

Expecting weaker organic growth in the second half of the year than in the first, Elior now anticipates organic sales growth of around 10% for the current financial year, and an adjusted EBITA margin towards the lower end of its initial range of 1.5 to 2%.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.